Physician profile
Douglas B Delay
NPI 1134117609
$766.14
in general payments reported to CMS, 2019-2025
18 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.24 · 2020: $13.52 · 2022: $86.96 · 2023: $239 · 2024: $180 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $602.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $117.22 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Eterna |
| Abbvie INC. | $106.13 | 2023 | Vraylar, Ubrelvy |
| Pfizer INC. | $103.31 | 2022-2025 | |
| Dexcom, INC. | $97.45 | 2022-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $59.50 | 2023-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Inceptiv |
| Novo Nordisk INC | $39.37 | 2024-2025 | Ozempic, Rybelsus |
| Amgen INC. | $31.98 | 2022 | |
| Amneal Pharmaceuticals LLC | $29.24 | 2025 | Unithroid |
| Astrazeneca Pharmaceuticals LP | $28.32 | 2020-2024 | Airsupra |
| Glaxosmithkline, LLC. | $24.18 | 2024 | Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $21.60 | 2025 | |
| Inspire Medical Systems, INC. | $20.44 | 2024 | Inspire |
| Dynavax Technologies Corporation | $17.23 | 2019 | |
| Lilly USA, LLC | $16.41 | 2024 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $16.25 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $13.26 | 2022 | |
| Sumitomo Pharma America, INC. | $13.20 | 2023 | Gemtesa |
| Strongbridge US INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Delay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.